ArticleAbdominal radiology (New York)2026
Feasibility, safety, and short-term efficacy of ultrasound-guided radiofrequency ablation for abdominal wall endometriosis: preliminary results from a single center.
Article in Abdominal radiology (New York), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo evaluate the feasibility, safety, and short-term outcomes of ultrasound-guided radiofrequency ablation (RFA) for abdominal wall endometriosis (AWE). MATERIALS AND
methodsThis retrospective single-center study included 19 patients with AWE (mean age, 35.5 ± 5.0 years) with 29 lesions who underwent ultrasound-guided RFA between December 2023 and January 2026. AWE was diagnosed based on clinical symptoms and imaging findings on ultrasonography and magnetic resonance imaging; biopsy was performed in atypical cases. RFA was performed using an 18-gauge electrode with the moving-shot technique under local anesthesia combined with intravenous analgesia. Complications were classified according to the SIR classification. Short-term technical efficacy was assessed at 3 months based on clinical symptoms and changes in lesion size on imaging.
resultsAll patients presented with abdominal pain, including 14 patients (73.7%) with cyclic pain. The mean preprocedural VAS score was 7.37 ± 1.42. A palpable mass was present in 17 patients (89.5%), and two patients (10.5%) had a history of prior surgery for AWE. The mean maximum lesion diameter decreased from 25.1 ± 17.47 mm before treatment to 13.4 ± 10.6 mm at 3 months (p < 0.01). The mean lesion volume decreased from 5.65 ± 7.41 mL to 1.27 ± 1.37 mL (p < 0.01). The mean VAS score decreased to 1.72 ± 2.78 at 3 months (p < 0.01). Three mild adverse events (15.8%) were observed.
conclusionUltrasound-guided RFA is a feasible and safe treatment option for AWE, providing short-term reductions in pain severity and lesion size.
Indexed as
Identifiers
42667387What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.